MedPath

SOUTHEASTERN GYNECOLOGIC ONCOLOGY

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
First Posted Date
2009-05-12
Last Posted Date
2013-09-20
Lead Sponsor
Southeastern Gynecologic Oncology
Target Recruit Count
60
Registration Number
NCT00897039
Locations
🇺🇸

Southeastern Gynecologic Oncology, LLP - Northside, Atlanta, Georgia, United States

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
First Posted Date
2007-04-27
Last Posted Date
2011-10-12
Lead Sponsor
Southeastern Gynecologic Oncology
Target Recruit Count
40
Registration Number
NCT00466986
Locations
🇺🇸

Southeastern Gynecologic Oncology, Atlanta, Georgia, United States

DOXIL for Consolidation Therapy in Ovarian Cancer.

Phase 2
Completed
Conditions
Ovarian Neoplasm
First Posted Date
2005-11-03
Last Posted Date
2011-10-12
Lead Sponsor
Southeastern Gynecologic Oncology
Target Recruit Count
45
Registration Number
NCT00248248
Locations
🇺🇸

Southeastern Gynecologic Oncology, Atlanta, Georgia, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.